Table 1. Non-viral vectors used to deliver genome editing agents in vivo.

A summary of recent non-viral vectors used for local and systemic in vivo delivery of nuclease- and oligonucleotide-based editing agents with corresponding references.

Local Delivery in vivo
Nonviral vector	Target gene	Disease	Editing Agent	Form of editing agent	Reference
Turbofect(Polymer)	HPV Genome	Cervical cancer	TALEN	pDNA	[26]
DNA NCs (DNA/Polymer)	GFP	-	CRISPR/Cas9	RNP	[27]
Polymer	Tumor suppressor genes	-	CRISPR/Cas9	pDNA	[28]
Lipofectamine (Lipid)	EGFP	-	CRISPR/Cas9	RNP	[29]
DNA-conjugated Gold/Polymer	DMD	DMD	CRISPR/Cas9	RNP	[30]
Lipid	TMC1	Hearing loss	CRISPR/Cas9	RNP	[31]
Polymer	β-globin	-	PNA	PNA	[32]
Polymer	CFTR	Cystic fibrosis	PNA	PNA	[33]

Systemic Delivery in vivo
Nonviral vector	Target gene	Disease	Editing Agent	Form of editing agent	Reference
Lipid	HBV DNA, PCSK9	HBV infection, hypercholesterolemia	CRISPR/Cas9	mRNA	[34]
Zwitterionic Amino Lipid	LoxP	-	CRISPR/Cas9	mRNA	[35]
Lipid	TTR	transthyretin (TTR)- mediated amyloidosis	CRISPR/Cas9	mRNA	[36]
Polymer	CCR5	HIV	PNA	PNA	[37]
Polymer	β-globin	β-thalassemia	γPNA	γPNA	[17]